Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sight Sciences (SGHT) EBITDA (2020 - 2025)

Sight Sciences (SGHT) has 6 years of EBITDA data on record, last reported at $25.4 million in Q4 2025.

  • For Q4 2025, EBITDA rose 312.62% year-over-year to $25.4 million; the TTM value through Dec 2025 reached -$8.1 million, up 84.04%, while the annual FY2025 figure was -$8.1 million, 84.04% up from the prior year.
  • EBITDA reached $25.4 million in Q4 2025 per SGHT's latest filing, up from -$7.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $25.4 million in Q4 2025 and bottomed at -$22.9 million in Q2 2022.
  • Average EBITDA over 5 years is -$12.6 million, with a median of -$13.6 million recorded in 2023.
  • Peak YoY movement for EBITDA: plummeted 106.43% in 2022, then surged 312.62% in 2025.
  • A 5-year view of EBITDA shows it stood at -$14.7 million in 2021, then fell by 15.88% to -$17.1 million in 2022, then soared by 34.85% to -$11.1 million in 2023, then dropped by 7.37% to -$11.9 million in 2024, then soared by 312.62% to $25.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $25.4 million in Q4 2025, -$7.9 million in Q3 2025, and -$11.7 million in Q2 2025.